Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    First Patient Dosed in Pidnarulex Study for Solid Tumors with HR Mutations
    https://unsplash.com/photos/tV-RX0beDp8

    First Patient Dosed in Pidnarulex Study for Solid Tumors with HR Mutations

    Homologous Recombination (HR) gene mutations play a role in genomic stability and plasticity, and sometimes work to repair cellular DNA damage. These mutations cause genetic information to be shared between…

    Continue Reading First Patient Dosed in Pidnarulex Study for Solid Tumors with HR Mutations
    Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL
    biker_becca / Pixabay

    Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL

    In the Phase 2 LOTIS-2 clinical trial, researchers evaluated the safety, efficacy, and tolerability of Loncastuximab tesirine for patients with aggressive diffuse large B-cell lymphoma (DLBCL). While there are treatment…

    Continue Reading Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL
    Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
    PhotoLizM / Pixabay

    Phase 3 Data Available on Pevonedistat for AML, MDS, CMML

    In the Phase 3 PANTHER clinical trial, also known as the Pevonedistat-3001 study, researchers were evaluating pevonedistat in conjunction with azacitidine for patients with acute myeloid leukemia (AML), myelodysplastic syndromes…

    Continue Reading Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
    DRC Confirms 2 Yellow Fever Cases
    Source: Pixabay.com

    DRC Confirms 2 Yellow Fever Cases

    On July 18, 2021, the World Health Organization (WHO) first reported two cases of yellow fever within the Democratic Republic of the Congo (DRC), shares Outbreak News Today. This rare…

    Continue Reading DRC Confirms 2 Yellow Fever Cases